The introduction of targeted therapy has transformed the landscape of treatment for chronic lymphocytic leukemia. Healio spoke with Ryan W. Jacobs, MD, head of the clinical trials program for CLL at Atrium Health’s Levine Cancer Institute, about the latest breakthroughs in CLL, the potential role of chimeric antigen receptor T-cell therapy, combination regimens in the pipeline and advice for physicians who are treating patients with this disease.
In this video, Ryan W. Jacobs, MD, discusses:
Please click on Next tab to advance through activity.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.